MARKET

ALNY

ALNY

Alnylam Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

130.92
-1.34
-1.01%
After Hours: 131.00 +0.08 +0.06% 17:22 09/21 EDT
OPEN
131.82
PREV CLOSE
132.26
HIGH
137.15
LOW
129.60
VOLUME
560.86K
TURNOVER
--
52 WEEK HIGH
167.33
52 WEEK LOW
73.32
MARKET CAP
15.18B
P/E (TTM)
-17.3056
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Arrowhead Pharma Reveals Positive Data On Drug To Treat Liver Disease; ARWR Stock Jumps
Investor's Business Daily · 5d ago
Hedge Funds Have Never Been This Bullish On Alnylam Pharmaceuticals, Inc. (ALNY)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Insider Monkey · 09/10 02:47
Citigroup Initiates Coverage On Alnylam Pharmaceuticals with Buy Rating, Announces Price Target of $170
Citigroup analyst Joel Beatty initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy rating and announces Price Target of $170.
Benzinga · 09/08 10:49
Should You Invest in Coronavirus ETFs?
MotleyFool.com · 09/06 09:27
Why Is Alnylam (ALNY) Down 14.8% Since Last Earnings Report?
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/05 16:32
Analyst Report: Alnylam Pharmaceuticals, Inc.
Find the latest Alnylam Pharmaceuticals, Inc. (ALNY) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance
Morningstar Research · 09/04 22:35
Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi Roundtable
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, will host an "RNAi Roundtable" webinar today at 12:00 p.m. ET, which will focus on progress across its ATTR amyloidosis programs. The Company will discuss the potential for a biannual subcutaneous dosing regimen
Business Wire · 09/03 12:30
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually:
Business Wire · 09/02 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 23 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALNY stock price target is 166.17 with a high estimate of 225.00 and a low estimate of 90.00.
EPS
Institutional Holdings
Institutions: 487
Institutional Holdings: 117.94M
% Owned: 101.70%
Shares Outstanding: 115.97M
TypeInstitutionsShares
Increased
136
5.70M
New
102
2.92M
Decreased
106
5.33M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/Director
Michael Bonney
President
Barry Greene
Chief Executive Officer/Director
John Maraganore
Chief Financial Officer/Executive Vice President
Jeffrey Poulton
Corporate Executive
Akshay Vaishnaw
Chief Operating Officer
Yvonne Greenstreet
Chief Human Resource Officer/Senior Vice President
Kelley Boucher
Executive Vice President/Secretary
Laurie Keating
Senior Vice President/Chief Scientific Officer
Kevin Fitzgerald
Director
Olivier Brandicourt
Independent Director
Dennis Ausiello
Independent Director
Marsha Fanucci
Independent Director
Margaret Hamburg
Independent Director
Steven Paul
Independent Director
David Pyott
Independent Director
Colleen Reitan
Independent Director
Amy Schulman
Independent Director
Phillip Sharp
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average ALNY stock price target is 166.17 with a high estimate of 225.00 and a low estimate of 90.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ:ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.